Combination therapy in epilepsy: when and what to use

Area of Science:

• Neurology
• Pharmacology
• Clinical Therapeutics

Background:

• Epilepsy treatment traditionally favored monotherapy.
• A significant portion of patients remain refractory to monotherapy.
• Modern antiepileptic drugs (AEDs) offer improved tolerability and pharmacokinetics.

Purpose of the Study:

• To re-evaluate the role of combination therapy in epilepsy management.
• To provide guidance on optimal AED combination strategies.
• To address the lack of robust evidence for current combination practices.

Main Methods:

• Review of current evidence and clinical practice recommendations for AED combination.
• Analysis of the efficacy and safety of monotherapy versus combination therapy.
• Exploration of pharmacomechanistic approaches to AED selection.

Main Results:

• Monotherapy remains the first-line treatment for newly diagnosed epilepsy.
• Combination therapy (two AEDs) is considered after failure of one or two monotherapy trials.
• Limited success is observed with three AEDs; four or more are generally ineffective.
• Excessive drug load increases toxicity risks.

Conclusions:

• Combination therapy for epilepsy requires further investigation.
• Randomized controlled trials are needed to establish optimal combination timing and methods.
• A pharmacomechanistic approach may guide AED selection.
• Balancing efficacy with toxicity is crucial in combination therapy.